Together with DKFZ and EORTC, AstraZeneca has joined the Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine.
WIN is a lobal network of academics, industries, payors and patient advocacy organizations which goal is to significantly improve survival and quality of life of cancer patients in the next three years. It was initiated in 2010 with leadership from the Institut Gustave Roussy (France) and The University of Texas MD Anderson Cancer Center (USA) as a first-of-it’s-kind, non-profit, non-governmental organization headquartered in Paris. Today the consortium counts 32 members in 5 continents.
Dr. Antoine Yver MD, Head of Oncology, AstraZeneca’s global medicines development unit, said: “Cancer is a devastating disease which has many forms, and there is still much to do in the search for new, targeted therapies to help patients. AstraZeneca has a rich heritage in oncology research and development and we can achieve a lot by joining forces with others to progress the best science and accelerate development of the next generation of medicines. At AstraZeneca, our aim is to advance our work in the area of personalized healthcare, helping to understand and address the underlying mechanisms of disease to get the right medicines to the right patients. We are delighted to join the WIN consortium and its rich global network of academic, pharmaceutical, information and translational business science partners. In doing so, it will provide access to our oncology pipeline, innovative science and our expertise to identify opportunities for combination therapies with potential to improve the lives of cancer patients everywhere.”